Skip to content
Clinical Trials – home

Spitalul Universitar De Urgenta Bucuresti

Research site

Romania Splaiul Independentei 169, 050098 Bucharest, Romania

  • 25 trials recruiting
  • Arteriosclerosis · Non-small cell lung cancer · Atrial fibrillation
  • Adults and children

About Specializations

Spitalul Universitar De Urgenta Bucuresti in Bucharest, Romania specialises in clinical trials of conditions such as Arteriosclerosis, Non-small cell lung cancer, Atrial fibrillation, Cardiac failure, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases and Heart Research at Spitalul Universitar De Urgenta Bucuresti

Clinical trials at this site focus strongly on cardiovascular diseases, especially conditions that raise the risk of heart attack, stroke, and heart failure. The research is aimed at testing new therapies and improving prevention strategies for people with high-risk heart and blood vessel disorders.

  • Acute coronary syndrome and recurrent cardiovascular event prevention
  • Atrial fibrillation, including stroke prevention and bleeding risk reduction
  • Heart failure with preserved or mildly reduced ejection fraction and systemic inflammation
  • Atherosclerotic cardiovascular disease with elevated lipoprotein(a)

These studies explore whether newer treatments can better protect patients from major cardiovascular complications and improve long-term outcomes.

Oncology and Targeted Cancer Treatment Studies

This site also contributes to neoplasm research, with trials centered on both blood cancers and advanced solid tumors. The main goal is to evaluate treatment effectiveness and safety for patients with difficult-to-treat cancers.

  • Isocitrate dehydrogenase 1 mutation-positive acute myeloid leukemia
  • Advanced non-small cell lung cancer without PD-L1 expression and with KRAS p.G12C mutation

The research includes studies of newer cancer therapies and combination approaches designed to improve disease control and survival.

Respiratory Tract Diseases in Severe Infection and Lung Cancer Research

Within respiratory tract diseases, clinical trials at the Bucharest hospital examine both serious lung infections and advanced lung cancer. The research is focused on finding better ways to treat severe illness and improve outcomes in hospitalized patients.

  • Severe community-acquired pneumonia
  • Advanced non-small cell lung cancer

These studies are designed to test new treatment options and support more effective care for patients with major respiratory conditions.

Reproductive and Urinary Physiological Phenomena in Women’s Health Research

Research in reproductive and urinary physiological phenomena includes studies related to pregnancy prevention and contraceptive care. The focus is on assessing whether a new contraceptive option is effective, safe, and acceptable for use.

  • Prevention of pregnancy
  • Contraceptive efficacy and tolerability

This area reflects practical clinical research aimed at improving family planning options and supporting women’s health.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Splaiul Independentei 169050098 BucharestRomania
Recruiting now
25 trials
Conditions studied
54

More sites in BucharestRomania

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

61 clinical trials

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB

Skin ulcer

Recruiting

Study on the Effectiveness of EscharEx and Amnion/Chorion Membrane Allograft for Patients with Venous Leg Ulcers

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Concentrate of proteolytic enzymes enriched in bromelain
  • Sponsor:Mediwound Ltd.
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Study on Eltrekibart and Mirikizumab for Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Mirikizumab
  • Sponsor:Eli Lilly & Co.

Cardiac failure

Recruiting

Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Study on the Safety of BHV-7000 for Adults with Hard-to-Treat Focal Onset Epilepsy

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:BHV-7000
  • Sponsor:Biohaven Therapeutics Ltd.

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

Investigational
Countries:RomaniaRomania
  • Participants:65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.